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ABSTRACT
MicroRNA contribute to tumor radiation resistance, which is an important 
clinical problem, and thus we are interested in identifying and characterizing their 
function. We demonstrate that miR-620 contributes to radiation resistance in cancer 
cells by increasing proliferation, and decreasing the G2/M block. We identify the 
hydroxyprostaglandin dehydrogenase 15-(nicotinamide adenine dinucleotide) 
(HPGD/15-PGDH) tumor suppressor gene as a direct miR-620 target, which results 
in increased prostaglandin E2 (PGE2) levels. Furthermore, we show that siRNA 
targeting of HPGD or administration of exogenous PGE2 recapitulates radioresistance. 
Targeting of the EP2 receptor that responds to PGE2 using pharmacological or genetic 
approaches, abrogates radioresistance. Tumor xenograft experiments confirm that 
miR-620 increases proliferation and tumor radioresistance in vivo. Regulation of PGE2 
levels via targeting of HPGD by miR-620 is an innovative manner by which a microRNA 
can induce radiation resistance.
INTRODUCTION
Over 50% of cancer patients will receive radiotherapy 
as part of their treatment. Despite delivery of a radical course 
of radiotherapy, tumor recurrences can occur, due to cellular 
mediators that promote radiation resistance [1], and this, in 
turn, can result in a more aggressive phenotype including 
increased proliferative capacity, nodal metastases, and poor 
prognosis [2–4]. To address this important clinical problem, a 
better understanding of the molecular mediators of resistance 
is required. We investigate the role of microRNA (miR) as 
mediators of tumor aggression and radiation resistance.
miR are short non-coding RNA that bind to the 3′ 
untranslated (UTR) region of mRNA, resulting in transcript 
degradation or inhibition of protein translation. A single 
miR may exhibit pleotropic effects due to regulation of 
multiple target mRNA. Their expression is known to be 
dysregulated in malignancies, and they are believed to 
contribute towards the pathogenesis of cancer [5]. Indeed, 
they can influence a broad range of cancer-related processes 
including proliferation, apoptosis, invasion and metastasis. 
It is now known that miR are involved in the response of 
tumor cells to radiotherapy (reviewed in [6] and [7]). Frank 
Slack and colleagues were the first to demonstrate that miR 
from the let-7 family could directly influence radiosensitivity 
in C. elegans and cancer cells [8]. Dicer and Drosha, which 
are essential enzymes involved in processing miR, are now 
known to be involved in activation of the DNA damage 
response (DDR) [9], further supporting the importance of 
miR in mediating cellular response to ionizing radiation. 
miR have been demonstrated to regulate radiosensitivity 
through targeting essential components of the DDR such as 
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Ataxia-teleangiectasia mutated (ATM) [10], DNA-dependent 
protein kinase catalytic subunit (DNA-PKcs) [11], histone 
variant H2AX [12], SNF2H [13], and the p53 (reviewed in 
[14]), and BRCA1 tumor suppressors [15]. Additionally, miR 
target critical survival pathways, such as the Akt [16, 17], 
mitogen-activated protein kinase (MAPK), and sphingosine-
phosphate 1 (S1P) signaling pathways [18]. Collectively, 
this results in alteration of cellular radiosensitivity. 
However, there are many additional miR that may influence 
radiosensitivity and these remain to be characterized.
We have now investigated the function of miR-620 in 
cancer radiation resistance and aggression. Only one paper 
has investigated the role of miR-620 to date [19]. Zhao 
et al., recently demonstrated that miR-620 is upregulated 
in human lung adenocarcinoma, and targets the Glypican 5 
(GPC5) tumor suppressor gene, which alters proliferation, 
migration and invasion [19]. We now demonstrate that miR-
620 overexpression promotes a radioresistant phenotype in 
a range of cancer cells, increases cellular proliferation and 
deregulates the G2/M checkpoint following irradiation, 
and enhances invasiveness. We discovered that miR-620 
directly targets the hydroxyprostaglandin dehydrogenase 
15-(nicotinamide adenine dinucleotide) (HPGD/15-
PGDH) tumor suppressor gene. HPGD is a key enzyme that 
inactivates prostaglandin E2 (PGE2), a proinflammatory 
lipid which promotes tumorigenesis [20, 21]. We show 
for the first time that miR-620 downregulation of HPGD 
promotes radioresistance. Additionally, we demonstrate that 
PGE2 administration can induce cancer cell radioresistance, 
and that knockdown of the EP2 receptor or pharmacological 
inhibition with an EP2 antagonist can abrogate this.
Together, our research provides novel insights into 
the role of miR-620 in promotion of cancer aggression and 
radiation resistance, and highlights the relevance of PGE2 
in radiation response.
RESULTS
miR-620 promotes increased survival, 
proliferation and G2/M checkpoint deregulation 
following irradiation
It is becoming evident that miR play an important 
role in tumor radiation response. We assessed the influence 
of a recently characterized miR-miR-620 (described in only 
one publication to date [19]), on cancer radiation response 
by transiently transfecting breast, prostate and pancreatic 
cancer cell lines (MDA-MB-231 breast cancer cells, non-
tumorigenic MCF10A breast cells, 22RV1 and DU145 
prostate cancer cells, PSN-1 and MIAPaCa-2 pancreatic 
cancer cells) with a miR-620 mimic or a control mimic and 
performing radiation clonogenic survival assays. All miR-
620 mimic transfected cell lines displayed increased radiation 
resistance compared to control mimic transfected cells (as 
indicated with increased radiation protection factors (RPF) in 
Figure 1), demonstrating that this effect is conserved between 
different cancer cell types. To determine if this resistance 
was due to an influence on cellular proliferation, we mock 
irradiated and irradiated MDA-MB-231 and DU145 cells 
that were transiently transfected with miR-620 mimic or 
control mimic and counted viable cells. miR-620 did not 
significantly alter proliferation of mock irradiated MDA-
MB-231 (1.1 ± 0.1 (miR-620) versus 1.0 (control), p = ns) or 
DU145 cells (1.1 ± 0.2 (miR-620) versus 1.0 (control), ns). 
However, it significantly increased proliferation following a 
6 Gy dose of ionizing radiation (IR), relative to control cells 
(MDA-MB-231: 1.2 ± 0.1 (miR-620) versus 1.0 (control); p 
< 0.05 and DU145: 1.7 ± 0.2 (miR-620) versus 1.0 (control), 
p < 0.05) (Figure 2A). Consistent with this, we discovered 
that the cell cycle profiles of MDA-MB-231 (G1 phase: 
76.6 ± 2.2% (miR-620) versus 80.3% ± 3.2% (control), ns; 
S phase: 8.1 ± 3.6% (miR-620) versus 5.7 ± 2.5% (control), 
ns; G2/M phase: 15.2 ± 0.2% (miR-620) versus 13.8 ± 2.0% 
(control), ns) and DU145 cells (G1 phase: 66.9 ± 1.5% (miR-
620) versus 68.1 ± 3.1% (control), ns; S phase: 8.6 ± 1.6% 
(miR-620) versus 7.8 ± 1.8% (control), ns; G2/M phase: 
24.5 ± 2.6% (miR-620) versus 23.9 ± 2.5% (control), ns) 
were not altered by miR-620 mimic in mock irradiated cells. 
However, 24 h after IR, the control MDA-MB-231 (G2/M 
phase: 48.4 ± 1.4% (miR-620) versus 54.0 ± 2.2% (control), 
p < 0.05) and DU145 cells (G2/M phase: 38.6 ± 8.6% (miR-
620) versus 51.3 ± 8.9% (control), p < 0.01) demonstrated an 
accumulation of cells in G2/M, which was significantly less 
in miR-620 transfected cells (Figure 2B). The extent of G2/M 
deregulation was lower in MDA-MB-231 cells compared to 
DU145 cells, however. Thus, increased expression of miR-620 
induces radioresistance, increases proliferative capacity and 
deregulation of the G2/M checkpoint following irradiation.
miR-620 increases cellular invasiveness
Increased invasiveness may promote metastatic 
spread, and thus we assessed the influence of miR-620 
on invasion using the Matrigel transwell assay. miR-620 
overexpression significantly increased the invasiveness 
of MDA-MB-231 and DU145 cells (1.7 ± 0.2 (miR-620) 
versus 1.0 (control); p < 0.05) and DU145 cells (2.2 ± 
0.15 (miR-620) versus 1.0 (control); p < 0.05) (Figure 3). 
Collectively, miR-620 can promote an aggressive 
phenotype in both MDA-MB-231 and DU145 cells by 
increasing survival and proliferation following radiation 
treatment, and enhancing invasive capacity.
HPGD is a target of miR-620 and mediates 
radiation resistance
To identify downstream effectors of miR-620 
potentially mediating radioresistance, we performed in 
silico target prediction using Targetscan Human release 
6.0 [22]. Targetscan identified the tumor suppressor gene, 
hydroxyprostaglandin dehydrogenase 15-(nicotinamide 
adenine dinucleotide) (HPGD/15-PGDH) as a putative 
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Figure 1: miR-620 promotes radiation resistance. MDA-MB-231, MCF10A, DU145, 22RV1, PSN-1 and MIAPaCa-2 cells were 
transiently transfected with control or miR-620 mimic, radiation clonogenic survival assays performed, and surviving fraction fitted to the 
linear-quadratic equation. Radiation protection factors (RPF) were determined by dividing the area under the curve (AUC) of the miR-620 
mimic by the AUC of the control mimic. There were statistically significant differences in AUC seen for all survival curves (p < 0.05).
Figure 2: miR-620 increases cellular proliferation and decreases G2/M phase accumulation following irradiation. A. MDA-
MB-231 and DU145 cells were transiently transfected with control or miR-620 mimic, mock irradiated or irradiated with 6 Gy of ionizing 
radiation, and total viable cells determined after 5 days. B. Cell cycle profiles of transiently transfected cells mock irradiated or irradiated with 6 
Gy of ionizing radiation. Mean, standard deviations and statistical significance are denoted; *p < 0.05, ***p < 0.01, ns, non-significant difference; 
n = 3 independent experiments.
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target of miR-620. HPGD is the key enzyme that 
inactivates a number of bioactive lipids, and is also a 
tumor suppressor [20]; its expression is reduced in a 
range of human cancers relative to corresponding normal 
tissue [23, 24 , 25]. HPGD catalyzes the degradation of 
prostaglandin E2 (PGE2), a bioactive eicosanoid that is 
associated with tumor progression [26, 27]. Its substrate, 
PGE2, has been previously demonstrated to provide 
radioprotection for normal intestinal stem cells [28–30]. 
Thus, we were interested in determining whether miR-
620 targets HPGD, thereby increasing levels of PGE2 to 
promote radioresistance.
Western blotting of lysates from MDA-MB-231 and 
DU145 cells transfected with control or miR-620 mimic 
established that HPGD was decreased at the protein level 
(Figure 4A). We co-transfected a luciferase reporter vector 
bearing the wildtype 3′UTR of HPGD into MDA-MB-231 
or DU145 cells with control or miR-620 mimic. The 
presence of miR-620 resulted in a significant reduction in 
normalized luciferase units relative to control (MDA- MB-
231: 0.72 ± 0.03, p < 0.05; DU145: 0.83 ± 0.03, p < 0.05) 
(Figure 4B). However, mutation of the predicted miR-
620 binding site reconstituted luciferase activity with no 
significant difference relative to control (MDA-MB-231: 
0.92 ± 0.04; DU145: 1.03 ± 0.01) (Figure 4B).
We next assayed cellular PGE2 levels (the key 
substrate for HPGD), and discovered that miR-620 mimic 
transfected cells have higher levels of PGE2 compared 
to control cells (MDA-MB-231: 29.8 ± 2.1 (miR-620) 
versus 16.0 ± 1.3 (control); p < 0.001; DU145: 38.4 ± 
1.2 (miR-620) versus 29.7 ± 1.6 (control); p < 0.01) 
(Figure 4C). Similarly, knockdown of HPGD with 
siRNA increased PGE2 levels (MDA-MB-231: 62.7 
± 4.6 (HPGD siRNA) versus 20.4 ± 1.7 (control); p < 
0.001; DU145: 19.4 ± 2.8 (HPGD siRNA) versus 13.2 
± 1.6 (control); p < 0.05) (Figure 4C). Knockdown of 
HPGD increased radiation resistance in both MDA-
MB-231 and DU145 cells (Figure 4D); reduction of 
HPGD protein levels were confirmed by western blotting 
(Supplementary Figure 1). For MDA-MB-231 cells, 
RPFs were similar between HPGD knockdown compared 
to miR-620 overexpression. However, for DU145 cells, 
HPGD knockdown resulted in a slightly lower RPF 
compared to miR-620 overexpression. Together, this 
demonstrated that HPGD knockdown could phenocopy 
the radioresistance seen in miR-620 overexpressing cells. 
Similarly, treatment with exogenous PGE2 rendered cells 
more resistant to radiation (MDA-MB-231: 0.097 ± 0.003 
(PGE2) versus 0.041 ± 0.003 (vehicle); p < 0.001; DU145: 
0.056 ± 0.004 (PGE2) versus 0.033 ± 0.002 (vehicle); 
p < 0.01) (Figure 4E). PGE2 signaling occurs through E 
Prostanoid (EP) receptors, and the EP2 receptor has been 
demonstrated to mediate radiosensitivity of normal small 
intestinal crypt cells [30]. Thus to determine whether the 
EP2 receptor was responsible for the observed radiation 
resistance induced by miR-620, we used siRNA to 
knockdown the EP2 receptor (Supplementary Figure 2) 
and performed radiation clonogenic survival assays in 
MDA-MB-231 cells stably overexpressing miR-620 or 
control miR (Figure 5). Knockdown of the EP2 receptor 
promoted cancer cell radiosensitivity to a greater degree 
in the miR-620 overexpressing cells relative to control 
cells. Similarly, pharmacological antagonism of the EP2 
receptor with AH-6809 was able to radiosensitize MDA-
MB-231 cells stably overexpressing control and miR-
620, with greater sensitization seen again in the miR-620 
overexpressing cells (Figure 5). This indicated that the 
EP2 receptor is an important intermediary for miR-620-
mediated radiation resistance.
miR-620 promotes tumor radiation resistance 
in vivo
To investigate the in vivo scenario of miR-
620 overexpression in tumors on growth and 
radiation growth delay, we used DU145 cells stably 
overexpressing miR-620 or control miR to produce 
subcutaneous tumors in athymic nude mice, followed 
by irradiation of the tumors with an 8 Gy dose of 
IR or mock IR (Figure 6A). The mock irradiated 
DU145-miR-620 tumors grew slightly more quickly 
than the DU145-control tumors (tumor volumes were 
Figure 3: miR-620 increases invasiveness. Invasion assays were performed on MDA-MB-231 and DU145 cells transiently 
transfected with control or miR-620 mimic. Mean, standard deviations and statistical significance are denoted; *p < 0.05; n = 3 independent 
experiments. Representative images are shown; scale bar = 250 µm.
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significantly larger based upon day 13 values, p < 0.05). 
A tumor growth delay was observed in both sets of 
tumors following irradiation, however the DU145-
miR-620 tumors began to regrow by day 16, whereas 
the DU145-control tumors did not continue to grow 
following irradiation (significant difference in 
tumor volumes based upon day 39 values, p < 0.05) 
(Figure 6A). This provided in vivo evidence that miR-
620 overexpression renders tumor radioresistant.
Tumors were removed and haemotoxylin and 
eosin staining was performed to identify regions of tumor 
necrosis. Irradiation increased tumor necrosis compared 
to unirradiated tumors, however there was no significant 
difference in percentage of necrosis visualized between 
DU145-miR-620 tumors and DU145-control tumors 
(32.94 ± 13.8% (miR-620) versus 33.7 ± 8.6% (control); 
p = ns) (Figure 6B). Ki-67 immunostaining indicated that the 
irradiated DU145-miR-620 tumors contained a significantly 
greater percentage of proliferative cells compared to control 
tumors (20.2 ± 1.8% (miR-620) versus 7.7 ± 1.2% (control); 
p < 0.001). In unirradiated tumors, there was no significant 
difference in proliferative cells (28.9 ± 3.9% (miR-620) versus 
25.7 ± 3.4% (control); p = ns) (Figure 6B). Since miR are 
noted to influence angiogenesis, we performed anti-CD31 
immunostaining followed by microvessel density (MVD) 
determination. MVD was not significantly altered in the 
Figure 4: HPGD is a target of miR-620, reduces cellular PGE-2 levels and induces radiation resistance. A. Representative 
western blot for HPGD and β-actin (loading control) levels in MDA-MB-231 and DU-145 cells transiently transfected with control (C) or 
miR-620 (620) mimic. B. MDA-MB-231 and DU145 cells were transiently cotransfected with wildtype (wt) or mutant (mt) HPGD 3′UTR 
luciferase vector, renilla vector and control or miR-620 mimic, then firefly luciferase assay performed and normalized to renilla signal. 
Sequences of the miR-620 binding sequence in the HPGD wt and mt 3′UTR are shown. C. MDA-MB-231 and DU145 cells transiently 
transfected with control or miR-620 mimic, or transiently transfected with control or HPGD siRNA were lysed and subjected to PGE2 
assays (representative experiments shown). D. MDA-MB-231 and DU145 cells were transiently transfected with control or HPGD siRNA 
and radiation clonogenic survival assays performed. E. MDA-MB-23 and DU145 cells were treated with PGE2 or vehicle, irradiated (4 
Gy or 6 Gy, respectively) and radiation clonogenic survival assays performed. Mean, standard deviations and statistical significance are 
denoted; *p < 0.05, **p < 0.01, ***p < 0.001; n = 3 independent experiments.
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DU145-miR-620 tumors compared to the DU145-control 
tumors that were not irradiated (28.2 ± 8.6 (miR-620) versus 
26.5 ± 7.3 (control); p = ns) or irradiated (18.0 ± 4.8 (miR-
620) versus 17.0 ± 5.3 (control); p = ns) (Figure 6B). Together, 
the immunohistochemistry data support our observations that 
miR-620 overexpression in DU145 miR-620 tumors promotes 
radiation resistance in vivo by increasing proliferation.
DISCUSSION
miR are an integral contributor to tumor radiation 
response, and thus elucidation of their function is 
essential to understanding this clinical problem. We 
provide novel evidence that miR-620 can promote 
radiation resistance in a range of cancer cells, including 
those that are inherently more radioresistant (i.e., 
pancreatic cancer). Our research provides the first 
link between miR regulation of PGE2 and radiation 
resistance, which occurs through alteration of PGE2 
levels via targeting of HPGD.
PGE2 can induce pleotropic tumorigenic effects 
that include enhanced proliferation, migration, invasion, 
and angiogenesis [31–33]. Signaling by PGE2 occurs 
through four EP receptors, and their expression levels 
Figure 5: EP2 receptor is responsible for miR-620-mediated radioresistance. MDA-MB-231 cells stably expressing control 
miR or miR-620 were transiently transfected with control or EP2 receptor siRNA (left panel), or were treated with vehicle (DMSO) or the 
EP2 antagonist AH-6809 (right panel), and radiation clonogenic survival assays performed. Mean and standard deviations are denoted; 
n = 3 independent experiments.
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are altered in cancer [34]. Additionally, since they are 
coupled to different signaling pathways, their phenotypic 
outcome (e.g., tumor progression or inhibition) can differ. 
Expression of EP2 and EP4 receptors are elevated in 
prostate cancer specimens compared to non-malignant 
prostate [35, 36]. EP4 expression increases during 
progression of prostate cancer from an androgen-sensitive 
state to castrate-resistance [37], highlighting the distinct 
phenotypic effects that these receptors can possess. The 
use of aspirin (which inhibits cyclo-oxygenase 1 (COX-
1) and 2 (COX-2) production) has been associated with a 
reduction in prostate cancer specific mortality in patients 
treated with radiotherapy or radical prostatectomy [38]. 
Mechanistically, it has been demonstrated that the COX-
2 inhibitor, celecoxib, induces prostate cancer death 
through the EP2 receptor [39]. In a murine model of cyclo-
oxygenase 2 (COX-2) driven mammary cancer, the EP1, 
EP2, and EP4 receptors were upregulated in tumor tissue 
[40]. Treatment of these tumors with celecoxib reduced 
tumor growth and reduced microvessel density [40]. 
Similarly, Tian and Schiemann observed that loss of EP2 
receptor reduced breast cancer growth, angiogenesis, and 
metastases in an orthotopic mouse model [41].
Accumulating evidence in the literature supports the 
overarching view that mechanisms resulting in increased 
production and signaling from PGE2 promotes tumor 
therapy resistance. Kurtova et al. recently reported that 
chemotherapy can induce PGE2 release in bladder cancer, 
and that this promotes cancer stem cell (CSC) repopulation 
and treatment resistance [42]. They noted that the CSC 
repopulation was blocked by a PGE2-neutralizing antibody 
and celecoxib-mediated blockade of PGE2 signalling. 
Although we have not specifically assayed for miR-620 and 
HPGD effects on CSC frequency in our cancer cell models, it 
is clear that miR-620 overexpression, HPGD knockdown or 
PGE2 treatment can increase clonogenic survival following 
irradiation. Clonogenic survival is the gold standard assay 
for irradiation studies, and takes into account all modes of 
cell death following irradiation including mitotic catastrophe, 
terminal senescence, apoptosis and presumably the influence 
Figure 6: miR-620 promotes tumor radioresistance in vivo. A. DU145 cells stably overexpressing control or miR-620 were 
grown as subcutaneous tumors, mock irradiated or irradiated with 8 Gy of ionizing radiation, and tumor volumes measured. B. Tumors were 
stained with H&E or immunostained with anti-ki67 or anti-CD31 antibodies, and necrosis, proliferation and mean vessel density (MVD) 
quantitated respectively. Scale bar indicates 2 mm (H&E) or 200 µm. Mean, standard deviations and statistical significance are denoted; 
*p < 0.05, ***p < 0.001.
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of CSC repopulation. The Li laboratory demonstrated that 
in irradiated tumors, activation of caspase 3 by apoptotic 
tumor cells induces PGE2, which can stimulate the growth 
of surviving tumor cells to repopulate the tumor [43]. PGE2 
appears to have a conserved effect in radiation response, 
since it increases hematopoietic stem cell survival after total 
body irradiation [44].
PGE2 has been shown to promote prostate cancer 
proliferation [39], and angiogenesis (via VEGF secretion) and 
this also appears to be mediated primarily by the EP2 receptor 
[32, 33]. We have now demonstrated that the EP2 receptor is 
also important for promotion of radiation resistance by miR-
620, as its genetic loss or pharmacological inhibition can 
radiosensitize cancer cells that overexpress miR-620. Thus, 
our research adds to the importance of the EP2 receptor in 
tumor progression and aggression, by demonstrating its role 
in promotion of cancer cell survival following irradiation. 
Together, our results provide support for a model whereby 
miR-620 targets HPGD, resulting in accumulation of 
HPGD’s substrate, PGE2, and signaling by PGE2 through the 
EP2 receptor results in cancer radiation resistance (Figure 7). 
Mohamed et al. demonstrated that elevated levels of the 
TMPRSS2-ERG fusion protein found in prostate cancer, 
can decrease HPGD expression by binding to the HPGD 
promoter, resulting in PGE2-dependent cancer proliferation 
and invasion [45]. However, epigenetic mechanisms also play 
an important role in regulation of HPGD expression. Thiel et 
al., discovered that HPGD expression is downregulated in 
gastric cancer, and provided evidence that this occurred partly 
through promoter methylation [24]. Our findings indicate 
that miR-targeting is another epigenetic mechanism that can 
regulate HPGD expression. Indeed, Lu and colleagues also 
recently demonstrated that HPGD is decreased by miR-21, 
and that increased PGE2 promotes cholangiocarcinoma 
growth [46]. In addition to regulation of PGE2 degradation 
by HPGD, it is known that the generation of PGE2 is also 
tightly regulated.
COX-2 is an inducible enzyme that catalyzes the 
synthesis of prostaglandins from arachindonic acid, and is a 
rate-limiting enzyme in PGE2 production. Not surprisingly, 
COX-2 induction is associated with increased production 
of PGE2 [47]. Analysis of data from the Radiation Therapy 
Oncology Group (RTOG)-9202 trial which randomized 
men with prostate cancer to short or long term androgen-
deprivation therapy, demonstrated that COX-2 expression 
was associated with biochemical failure and distant metastasis 
[48]. A more recent analysis of this trial data indicated that 
high expression of COX-2 in prostate cancer, in combination 
with three other genes (ki-67, MDM2 and p16), predicted for 
an increased risk of developing distant metastases following 
androgen deprivation therapy and radiotherapy [49]. In 
addition to its utility as a prognostic biomarker, research 
has also investigated COX-2 as a therapeutic target [50]. 
Multiple preclinical studies have demonstrated proof-of-
principle of COX-2 inhibition for enhancement of tumor 
radiation response (reviewed in [51]). Several early phase 
trials are investigating the COX-2 inhibitor, celecoxib, as a 
radiosensitizer in a range of malignancies including prostate 
cancer [52], locally advanced non-small cell lung cancer 
[53], locally advanced cervical cancer [54], rectal cancer, 
and recurrent head and neck cancer [55]. The acute toxicities 
have generally been well-tolerated, although Herrera et al. 
reported higher than expected late complications [54]. COX-2 
inhibitors are also known to increase the risk of cardiovascular 
events in patients [56], and thus this may limit their utility as 
tumor radiosensitizers. We demonstrated that specific blockade 
of the EP2 receptor has therapeutic efficacy in reversing 
radioresistance, and thus the use of specific inhibitors of PGE2 
signaling such as EP2 antagonists may be desirable, since they 
may potentially limit or avoid side-effects seen with COX-2 
inhibitors. Nevertheless, future investigations are needed to 
establish the potential radiosensitization of critical normal 
tissues (e.g., small intestine, spinal cord) by EP2 antagonists, 
and thereby allow determination of the therapeutic ratio.
Figure 7: Proposed model of miR-620 on cancer survival in response to radiation treatment. PGE2 is synthesized through 
the action of COX1 and COX2 on arachidonic acid, followed by PGE synthase. This is counteracted by degradation of PGE2 by its major 
catabolizing enzyme, HPGD. miR-620 specifically targets HPGD for degradation which results in increased PGE2 levels, and signaling 
through the EP2 receptor promotes cancer cell survival.
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The post-transcriptional regulation of COX-2 
by different miR has been well described by multiple 
research groups (reviewed in [57]). In this context, these 
miR would presumably exhibit a tumor inhibiting function 
by downregulating PGE2 production. Our research adds a 
new element of complexity, by demonstrating for the first 
time, that miR-620 can target the major PGE2 catabolizing 
enzyme, HPGD, and promote tumor radiation resistance. 
Additionally, we provide evidence that pharmacological 
antagonism of the EP2 receptor may be a useful 
therapeutic strategy to enhance tumor radiation response.
MATERIALS AND METHODS
Cell lines and cell culture
Human prostate adenocarcinoma (DU145, 22RV1), 
human breast adenocarcinoma (MDA-MB-231) and human 
pancreatic adenocarcinoma (MIAPaCa-2, PSN-1) cell lines 
were purchased from American Type Culture Collection 
(ATCC; VA, USA). Early passage cell lines were cultured 
in Dulbecco’s modified Eagle medium (DMEM) with the 
exception of PSN-1 which were cultured in RPMI-1640 
medium, containing 4.5 g/L glucose (Invitrogen, Ontario, 
Canada) supplemented with 10% fetal bovine serum (FBS) 
(Invitrogen, Ontario, Canada) and penicillin (100 U/mL) – 
streptomycin (100 μg/mL) (Invitrogen, Ontario, Canada) 
(hereafter referred to as 10% DMEM), and maintained 
in a humidified 37°C incubator with 5% CO2. MCF10A 
immortalized human mammary epithelial cells were kindly 
provided by Dr. Senthil Muthuswamy, and cultured in 
DMEM/F12 supplemented with 5% horse serum (Invitrogen, 
Ontario, Canada), epidermal growth factor (EGF) (20 ng/mL), 
(Sigma-Aldrich, Ontario, Canada) hydrocortisone (0.5 
mg/mL) (Sigma-Aldrich, Ontario, Canada), cholera toxin 
(100 ng/mL) (Sigma-Aldrich, Ontario, Canada), insulin 
(10 ug/mL) (Sigma-Aldrich, Ontario, Canada) and penicillin-
streptomycin. Cell lines were passaged when they reached 
approximately 80% confluency and were regularly tested 
with MycoAlert (Lonza, Ontario, Canada) to ensure the 
absence of mycoplasma contamination.
Transfection of microRNA mimics and siRNA
3 × 105 cells were seeded into 6-well plates, then 
16 h later, miScript miRNA miR-620 mimic or miRNA 
control mimic (Thermo Fisher Scientific, MA, USA) were 
mixed with 6 μL of DharmaFECT transfection reagent 
(Thermo Fisher Scientific, MA, USA) and DMEM as per 
the manufacturer’s instructions, then added to 10% DMEM 
for transfection of the cells. For siRNA transfections, 
control and siRNA for HPGD or EP2 receptor (Santa Cruz 
Biotechnology, CA, USA) were transiently transfected 
into cells using Lipofectamine 2000 (Invitrogen, Ontario, 
Canada) as per manufacturer’s recommendations, and 24 h 
later, radiation clonogenic survival assays (described below) 
were performed on the transfected cells.
EP2 receptor antagonist
Vehicle (DMSO), or EP2 antagonist (AH-6809; 
Santa Cruz Biotechnology, USA) was added at 40 μM to 
cells for 3 hrs prior to irradiation.
Generation of stable overexpressing miR-620 cell lines
Cells were transduced with shMIMIC miR-
620 or non-silencing control lentiviral particles as per 
manufacturer’s instructions (ThermoScientific, PA, USA), 
selected using puromycin for two weeks, and stable 
transductants were pooled.
Cellular proliferation assay
24 h after transient transfection of cells with miR-
620 or control mimic, cells were seeded in triplicate in 
10% DMEM in 6-well plates and mock irradiated or 
irradiated with a 6 Gy dose of IR 6 hr later. Four days 
later, cells were trypsinized and total viable cell number 
determined using the Countess automated cell counter 
(Life Technologies, Ontario, Canada); cell numbers were 
normalized relative to control cells.
Cell cycle analysis
Cells were mock irradiated or irradiated with a 6 Gy 
dose of IR, then 24 h later, cells were trypsinized, washed in 
PBS and fixed in ice-cold 80% ethanol in Hank’s Buffered 
Salt Solution (HBSS) (137 mM NaCl, 5.4 mM KCl, 0.25 
mM Na2HPO4, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM 
MgSO4, 4.2 mM NaHCO3) for 30 min on ice. Fixed cells 
were collected by centrifugation, washed twice with PBS, 
and resuspended in 50 μg/mL propidium iodide (Sigma-
Aldrich, Ontario, Canada) with 0.6% NP-40 (Thermo Fisher 
Scientific, IL, USA) and 0.1 mg/mL RNAse A in HBSS for 
30 min at room temperature in the dark. Cells were then 
collected by centrifugation, resuspended in PBS, and 20, 000 
events captured on a FACSCalibur flow cytometer (BD 
Biosciences, Ontario, Canada) and cell cycle profile 
analyzed using FlowJo 10.0.4 (Tree Star Inc., OR, USA).
Radiation clonogenic survival assay
Cells were seeded onto a six-well plate in 10% DMEM 
in triplicate and mock irradiated (0 Gy) or irradiated with 2, 4, 
or 6 Gy dose of IR, respectively. Then cells were placed in a 
humidified CO2 incubator at 37
oC to allow colonies to form. 
Colonies were stained with crystal violet staining solution 
(0.5% crystal violet (Sigma-Aldrich, Ontario, Canada), 25% 
methanol) and counted. Survival was expressed as the relative 
plating efficiencies of the treated cells compared with that of 
the mock-irradiated cells. The experiments were performed 
three separate times. Radiation dose-response curves were 
created by fitting the data to the linear-quadratic equation 
S = e-αD−βD2 using GraphPad Prism 5.0 (GraphPad Software 
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Inc, CA, USA), where S is the surviving fraction, α and β are 
inactivation constants, and D is the dose in Gy. The area under 
the curves (AUC) which represent the mean inactivation dose 
(MID) were also calculated using GraphPad Prism. The 
radiation protection factor (RPF) was calculated by dividing 
the MID of the test cells by the MID of control cells.
Real-time quantitative PCR
For microRNA expression, total microRNA was 
extracted from cells or tumors using the mirVana miRNA kit 
(Invitrogen, Ontario, Canada) according to the manufacturer’s 
instructions. cDNA was synthesized using the miScript II 
RT kit (Qiagen, Ontario, Canada) as per manufacturer’s 
instructions. The mature miR-620 expression level was 
quantified through quantitative real-time PCR using the mi-
Script SYBR Green PCR kit (Qiagen, Ontario, Canada) and 
miScript Primer Assay for SNORD61 and miR-620 (Qiagen, 
Ontario, Canada) on the StepOnePlus Real-time PCR system 
(Life Technologies, Ontario, Canada). For gene expression, 
RNA was extracted using the RNeasy Mini kit (Qiagen, 
Ontario, Canada) and cDNA synthesized using Omniscript 
RT kit (Qiagen, Ontario, Canada) as per manufacturer’s 
instructions. HPGD expression level was quantified through 
quantitative real-time PCR using the QuantiTect SYBR Green 
PCR kit (Qiagen, Ontario, Canada) on the StepOnePlus Real-
time PCR system. For both microRNA and mRNA, expression 
levels were calculated using the comparative Ct method via 
StepOne Software (Life Technologies, Ontario, Canada), 
and relative expression levels normalized to SNORD61 (for 
microRNA) or GAPDH (for mRNA)). Primer sequences: 
HPGD: forward 5′-TGCTTCAAAGCATGGCATAG-3′, 
reverse 5′-AACAAAGCCTGGACAAATGG-3′.
Matrigel transwell invasion assay
Cells were serum starved overnight (0.1% DMEM), 
then 2 × 105 cells were seeded on top of 8 μm transwell 
inserts (BD Biosciences, Ontario, Canada) with 0.1% 
DMEM and pre-coated with Matrigel (Becton, Dickinson 
and Company, Ontario, Canada); 10% DMEM was used as a 
chemoattractant. After 24 h, cells that had invaded through the 
Matrigel coated transwell inserts were fixed, stained by Kwik-
Diff Stain (Thermo Fisher Scientific, Ontario, Canada) and 
number of invading cells counted under 10 × using a Leica 
DM LB2 microscope (Leica Microsystems, Ontario, Canada).
Western blotting
Cells were lysed in ice-cold radioimmunoassay 
precipitation assay (RIPA) lysis buffer (50 mM Tris pH 
7.5, 150 mM NaCl, 2 mM EDTA pH 8.0, 0.5% (v/v) 
Triton X-100, and Complete protease inhibitor cocktail 
(Roche, Quebec, Canada)). Cell debris and insoluble 
material were removed by centrifugation at 12, 000 g 
at 4oC for 20 min. Following protein quantitation using 
the Bradford protein assay (Bio-Rad, Ontario, Canada), 
25 μg of lysate was loaded per lane and proteins resolved 
by 4%–20% gradient SDS-PAGE gel, wet-transferred to 
polyvinylidene fluoride membranes (EMD Millipore, MA, 
USA), and the membranes were incubated in 5% nonfat 
dry milk in Tris-buffered saline Tween-20 (TBST) (10 
mM Tris-Base, 150 mM NaCl, 0.05% Tween-20; pH 7.4) 
for 1 h at room temperature to block nonspecific antibody 
binding, followed by incubation with primary antibody in 
5% milk in TBST overnight at 4°C with gentle agitation. 
The membranes were washed three times for 10 min each 
in TBST, then incubated in TBST at room temperature for 
1 h, followed by three 10-min washes with TBST. Protein-
antibody binding on the membranes was detected with the 
use of enhanced chemiluminescence (ECL) Plus solution 
(GE Healthcare Life Sciences, Quebec, Canada) followed 
by exposure of the membranes to x-ray film (FujiFilm, 
Ontario, Canada). Anti-HPGD antibody was purchased 
from Sino Biological, China. Anti-β-actin antibody was 
purchased from Santa Cruz Biotechnology, CA, USA.
Luciferase assay
For HPGD 3′UTR luciferase assays, cells were 
transiently co-transfected with a HPGD 3′UTR luciferase 
reporter plasmid or HPGD 3′UTR luciferase reporter 
plasmid with mutations in the predicted miR-620 binding 
site, pcDNA3 vector constitutively expressing Renilla 
luciferase, and miScript miRNA miR-620 mimic or 
control mimic. 24 h later, cells were processed for firefly 
luciferase and Renilla luciferase activity using the Dual 
Glo Luciferase Assay System (Promega, WI, USA). To 
normalize for transfection efficiency, the firefly luciferase 
activity was normalized to the Renilla luciferase activity.
PGE-2 assay
Cells were lysed in homogenization buffer, lysates 
sonicated, and processed through a QIA Shredder 
(Qiagen, Ontario, Canada). Lysate was then clarified by 
centrifugation, total protein concentrations determined, 
and PGE2 levels assayed using the Prosaglandin E2 EIA 
kit (Cayman Chemical Company, Michiagan, USA) as per 
manufacturer’s recommendations.
Tumor xenograft experiments
All experiments involving mice were performed 
according to University of Toronto and Sunnybrook Research 
Institute guidelines, using a peer-reviewed animal protocol. 
Three million DU145-control and DU145-miR-620 cells 
were mixed in a 1:1 (vol:vol) ratio with Growth Factor 
Reduced Matrigel (Becton, Dickinson and Company, Ontario, 
Canada), and the mixture was injected subcutaneously into 
the right flanks of 6 to 7-week-old female athymic nude mice 
(Harlan, Ontario, Canada). Tumor volume (in mm3) was 
determined by caliper measurements performed every 3 to 
4 days and calculated by using the modified ellipse formula 
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(volume = length × width2/2). When the xenograft tumor 
volumes reached approximately 100 mm3, mice were 
randomly assigned to mock IR or an 8 Gy dose of IR 
delivered to the tumor, and tumor volumes determined every 
3–4 days after IR. When tumor volumes reached three times 
the starting volume (except for DU145-control irradiated 
tumors; these tumors were harvested at day 48), the mice 
were killed by cervical dislocation, and their tumors were 
excised, cut in half, with one half placed in Tissue-Tek O.C.T. 
compound (Fisher Scientific Co., Ottawa, Ontario) and stored 
at −80°C until cryosectioning and the remaining half flash-
frozen in liquid nitrogen.
Immunohistochemistry
To quantitate tumor necrosis, cellular proliferation 
and angiogenesis, five micron thick tumor sections 
were stained with haematoxylin and eosin (H&E), 
anti-Ki-67 or anti-CD31 antibodies respectively (n = 3 
tumors per group) as previously described [58]. Areas of 
necrosis were delineated, quantitated and expressed as a 
percentage of total tumor area. The percentage of Ki-67 
positive nuclei were quantitated from 6 representative 
fields. Microvessel density (MVD) was determined by 
finding tumor areas with the highest vascularity (hot 
spots) on low magnification (5×), and in each hot spot, 
CD31 positive microvessels were counted under high 
magnification (20×), with a positive microvessel defined 
as an endothelial cell or endothelial cell cluster that was 
clearly separated from adjacent microvessels, tumor cells, 
and other connective tissue elements.
Statistical analysis
All statistical tests were two-sided, and the 
statistical analysis was performed using the GraphPad 
Prism version 5.0 program (GraphPad Software, CA, 
USA). Statistical significance was defined as p < 0.05, 
and ns = non-significant. The Student t-test was used to 
compare the mean values between two groups. Data are 
presented as mean values with standard deviations unless 
otherwise noted.
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